Such treatments with mortalin-affecting SMR peptides are able to re-establish the complement-mediated cytotoxicity toward breast cancer cells and sensitize the latter to antibody/complement-based immunotherapy. This evidence concerns the gene HSPA9 and breast carcinoma.